Modulating the S100B-RAGE axis by using FPS-ZM1, a high-affinity RAGE-specific inhibitor, has shown a reduction in neuroinflammation and progressive improvement in cognitive functions in AD models. This evidence concerns the gene S100B and Alzheimer disease.